Details

Autor(en) / Beteiligte

• Bacq, Alexandre
• Depaulis, Antoine
• Castagné, Vincent
• Le Guern, Marie-Emmanuelle
• Wirrell, Elaine C.
• Verleye, Marc

Titel

An Update on Stiripentol Mechanisms of Action: A Narrative Review

Ist Teil von

• Advances in therapy, 2024-04, Vol.41 (4), p.1351-1371

Ort / Verlag

Cheshire: Springer Healthcare

Erscheinungsjahr

2024

Link zum Volltext

Quelle

SpringerLink

Beschreibungen/Notizen

• Stiripentol (Diacomit ® ) (STP) is an orally active antiseizure medication (ASM) indicated as adjunctive therapy, for the treatment of seizures associated with Dravet syndrome (DS), a severe form of childhood epilepsy, in conjunction with clobazam and, in some regions valproic acid. Since the discovery of STP, several mechanisms of action (MoA) have been described that may explain its specific effect on seizures associated with DS. STP is mainly considered as a potentiator of gamma-aminobutyric acid (GABA) neurotransmission: (i) via uptake blockade, (ii) inhibition of degradation, but also (iii) as a positive allosteric modulator of GABA A receptors, especially those containing α3 and δ subunits. Blockade of voltage-gated sodium and T-type calcium channels, which is classically associated with anticonvulsant and neuroprotective properties, has also been demonstrated for STP. Finally, several studies indicate that STP could regulate glucose energy metabolism and inhibit lactate dehydrogenase. STP is also an inhibitor of several cytochrome P450 enzymes involved in the metabolism of other ASMs, contributing to boost their anticonvulsant efficacy as add-on therapy. These different MoAs involved in treatment of DS and recent data suggest a potential for STP to treat other neurological or non-neurological diseases.